Venetoclax Basket Trial for High Risk Hematologic Malignancies
Status:
Not yet recruiting
Trial end date:
2027-04-02
Target enrollment:
Participant gender:
Summary
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in
pediatric and young adult patients with hematologic malignancies, including myelodysplastic
syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and
acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL).
The names of the study drugs involved in this study are below. Please note this is a list for
the study as a whole, participants will receive drugs according to disease cohort.
- Venetoclax
- Azacitidine
- Cytarabine
- Methotrexate
- Hydrocortisone
- Leucovorin
- Dexamethasone
- Vincristine
- Doxorubicin
- Dexrazoxane
- Calaspargase pegol
- Hydrocortisone
Phase:
Phase 1
Details
Lead Sponsor:
Andrew E. Place
Collaborators:
AbbVie Boston Children's Hospital Children's Cancer Research Fund Servier University of Colorado, Denver